JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses

Antiviral Research

Volumn 133, Issue , 2016, Pages 23-31

  Fu, Yu ^a   Gaelings, Lana ^a   Söderholm, Sandra ^a,b   Belanov, Sergei ^a   Nandania, Jatin ^a   Nyman, Tuula A ^a   Matikainen, Sampsa ^b   Anders, Simon ^a   Velagapudi, Vidya ^a   Kainov, Denis E ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ANTIVIRUS AGENT; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GEMCITABINE; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 8; JNJ 63623872; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYMERASE BASIC 2 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA; CYTOKINE; PB2 PROTEIN, INFLUENZAVIRUS A; PROTEIN BINDING; RNA DIRECTED RNA POLYMERASE; VIRAL PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL DEATH; CELL FUNCTION; CELL METABOLISM; CELL PROTECTION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLUENZA A; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); MACROPHAGE; METABOLOMICS; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; TRANSCRIPTOMICS; VIRUS REPLICATION; BINDING SITE; CHEMISTRY; CLUSTER ANALYSIS; CONFORMATION; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; HOST PATHOGEN INTERACTION; INFLUENZA; INFLUENZA A VIRUS; METABOLISM; METABOLOME; MOLECULAR MODEL; PHYSIOLOGY; PROCEDURES; PROTEIN DOMAIN; VIROLOGY;

ANTIVIRAL AGENTS; BINDING SITES; CLUSTER ANALYSIS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION PROFILING; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MACROPHAGES; METABOLOME; METABOLOMICS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; RNA REPLICASE; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84979787985     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.07.008     Document Type: Article

References (43)

1. Anastasina, M., et al. The C terminus of NS1 protein of influenza A/WSN/1933(H1N1) virus modulates antiviral responses in infected human macrophages and mice. J. Gen. Virol. 96 (2015), 2086–2091, 10.1099/vir.0.000171.
2. Belanov, S.S., et al. Genome-wide analysis of evolutionary markers of human influenza A(H1N1)pdm09 and A(H3N2) viruses may guide selection of vaccine strain candidates. Genome Biol. Evol. 7 (2015), 3472–3483, 10.1093/gbe/evv240.
3. Byrn, R.A., et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob. Agents Chemother. 59 (2015), 1569–1582, 10.1128/AAC.04623-14.
4. Ciccolini, J., et al. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother. Pharmacol., 2016, 10.1007/s00280-016-3003-0.
5. Clark, M.P., et al. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J. Med. Chem. 57 (2014), 6668–6678, 10.1021/jm5007275.
6. Denisova, O.V., et al. Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection. J. Biol. Chem. 287 (2012), 35324–35332, 10.1074/jbc.M112.392142.
7. Denisova, O.V., et al. Akt inhibitor MK2206 prevents influenza pH1N1 virus infection in vitro. Antimicrob. Agents Chemother. 58 (2014), 3689–3696, 10.1128/AAC.02798-13.
8. Edgar, R.C., MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinforma., 5(113), 2004, 10.1186/1471-2105-5-113.
9. Edinger, T.O., et al. Entry of influenza A virus: host factors and antiviral targets. J. Gen. Virol. 95 (2014), 263–277, 10.1099/vir.0.059477-0.
10. Finethy, R., et al. Guanylate binding proteins enable rapid activation of canonical and noncanonical inflammasomes in Chlamydia-infected macrophages. Infect. Immun. 83 (2015), 4740–4749, 10.1128/IAI.00856-15.
11. Fox, J.M., et al. Interferon lambda upregulates IDO1 expression in respiratory epithelial cells after influenza virus infection. J. Interferon Cytokine Res. 35 (2015), 554–562, 10.1089/jir.2014.0052.
12. Friedman, K., et al. Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. Mod. Pathol., 2016, 10.1038/modpathol.2016.54.
13. Gold, E.S., et al. 25-Hydroxycholesterol acts as an amplifier of inflammatory signaling. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 10666–10671, 10.1073/pnas.1404271111.
14. Hoffmann, E., et al. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 6108–6113, 10.1073/pnas.100133697.
15. Hu, Y., et al. Guanylate binding protein 4 negatively regulates virus-induced type I IFN and antiviral response by targeting IFN regulatory factor 7. J. Immunol. 187 (2011), 6456–6462, 10.4049/jimmunol.1003691.
16. Kearse, M., et al. Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics 28 (2012), 1647–1649, 10.1093/bioinformatics/bts199.
17. Kim, B.H., et al. A family of IFN-gamma-inducible 65-kD GTPases protects against bacterial infection. Science 332 (2011), 717–721, 10.1126/science.1201711.
18. Krapp, C., et al. Guanylate binding protein (GBP) 5 is an interferon-inducible inhibitor of HIV-1 infectivity. Cell Host Microbe 19 (2016), 504–514, 10.1016/j.chom.2016.02.019.
19. Li, T.C., et al. Clinical implications of antiviral resistance in influenza. Viruses 7 (2015), 4929–4944, 10.3390/v7092850.
20. Liu, Q., et al. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol. Immunol. 13 (2016), 3–10, 10.1038/cmi.2015.74.
21. Loregian, A., et al. Antiviral strategies against influenza virus: towards new therapeutic approaches. Cell Mol. Life Sci. 71 (2014), 3659–3683, 10.1007/s00018-014-1615-2.
22. Meunier, E., et al. Interferon-inducible GTPases in cell autonomous and innate immunity. Cell Microbiol. 18 (2016), 168–180, 10.1111/cmi.12546.
23. Muller, K.H., et al. Emerging cellular targets for influenza antiviral agents. Trends Pharmacol. Sci. 33 (2012), 89–99, 10.1016/j.tips.2011.10.004.
24. Nguyen, N.T., et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 19961–19966, 10.1073/pnas.1014465107.
25. Nikkanen, J., et al. Mitochondrial DNA replication defects disturb cellular dNTP pools and remodel one-carbon metabolism. Cell Metab. 23 (2016), 635–648, 10.1016/j.cmet.2016.01.019.
26. Nordmann, A., et al. A new splice variant of the human guanylate-binding protein 3 mediates anti-influenza activity through inhibition of viral transcription and replication. FASEB J. 26 (2012), 1290–1300, 10.1096/fj.11-189886.
27. Ohman, T., et al. Cytosolic RNA recognition pathway activates 14-3-3 protein mediated signaling and caspase-dependent disruption of cytokeratin network in human keratinocytes. J. Proteome Res. 9 (2010), 1549–1564, 10.1021/pr901040u.
28. Pan, W., et al. Guanylate-binding protein 1 participates in cellular antiviral response to dengue virus. Virol. J., 9(292), 2012, 10.1186/1743-422X-9-292.
29. Pirhonen, J., Sareneva, T., Kurimoto, M., Julkunen, I., Matikainen, S., Virus infection activates IL-1 beta and IL-18 production in human macrophages by a caspase-1-dependent pathway. J. Immunol. 162:12 (1999), 7322–7329.
30. Ritchie, M.E., et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res., 43, 2015, e47, 10.1093/nar/gkv007.
31. Roman-Garcia, P., et al. Vitamin B(1)(2)-dependent taurine synthesis regulates growth and bone mass. J. Clin. Invest 124 (2014), 2988–3002, 10.1172/JCI72606.
32. Saha, B., et al. Gene modulation and immunoregulatory roles of interferon gamma. Cytokine 50 (2010), 1–14, 10.1016/j.cyto.2009.11.021.
33. Santos, A., et al. Pyrimidine-5'-nucleotidase Campinas, a new mutation (p.R56G) in the NT5C3 gene associated with pyrimidine-5'-nucleotidase type I deficiency and influence of Gilbert's Syndrome on clinical expression. Blood Cells Mol. Dis. 53 (2014), 246–252, 10.1016/j.bcmd.2014.05.009.
34. Schmidt, S.V., et al. New insights into IDO biology in bacterial and viral infections. Front. Immunol., 5(384), 2014, 10.3389/fimmu.2014.00384.
35. Shenoy, A.R., et al. GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals. Science 336 (2012), 481–485, 10.1126/science.1217141.
36. Smyth, G.K., Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol., 3, 2004, 10.2202/1544–6115.1027 Article3.
37. Soderholm, S., et al. Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine. Antivir. Res. 126 (2016), 69–80, 10.1016/j.antiviral.2015.12.011.
38. Tang, Y., et al. Herc5 attenuates influenza A virus by catalyzing ISGylation of viral NS1 protein. J. Immunol. 184 (2010), 5777–5790, 10.4049/jimmunol.0903588.
39. Vanderlinden, E., et al. Emerging antiviral strategies to interfere with influenza virus entry. Med. Res. Rev. 34 (2014), 301–339, 10.1002/med.21289.
40. Wang, X., et al. RNA interference screening of interferon-stimulated genes with antiviral activities against classical swine fever virus using a reporter virus. Antivir. Res. 128 (2016), 49–56, 10.1016/j.antiviral.2016.02.001.
41. Wang, Y., et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat. Med. 16 (2010), 279–285, 10.1038/nm.2092.
42. Zhu, Z., et al. Nonstructural protein 1 of influenza A virus interacts with human guanylate-binding protein 1 to antagonize antiviral activity. PLoS One, 8, 2013, e55920, 10.1371/journal.pone.0055920.
43. Zumla, A., et al. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. Lancet Infect. Dis. 16 (2016), e47–63, 10.1016/S1473-3099(16)00078-5.